BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

MARS Bioimaging Secures First Clinical Sale of Portable Photon-Counting CT System

Christchurch-based Reform Radiology becomes inaugural clinical customer as New Zealand-developed photon-counting CT technology enters routine clinical&nb...

August 05, 2026 | News

GlycoNex Doses First Patient in Phase I Trial of Novel Glycan-Targeting ADC GNX1021

GlycoNex Inc. announced that the first patient has been successfully dosed in the First-in-Human (FIH) Phase I clinical trial of GNX1021, the Company's nov...

August 04, 2026 | News

From Market Access to Long-Term Growth: Rethinking Biopharma Expansion in APAC

BioPharma APAC speaks with Girisan Kariangal, Regional Vice President – Business Development & Alliance Management, Menarini Asia-Pacific, on the...

August 04, 2026 | Interaction

Ractigen's World's First saRNA Therapy for Ocular Diseases Advances to Global Clinical Development Following U.S. FDA IND Clearance

RAG-1C achieves dual IND clearances from both U.S. FDA and China CDE, paving the way for global clinical development of the world's first saRNA therapy f...

August 03, 2026 | News

Thermo Fisher Launches Real-World Registry to Advance Long-Term Vitiligo Research

Thermo Fisher Scientific, the world leader in serving science, announced the launch of the PPD™ CorEvitas™ Vitiligo Registry, a prospective, ob...

July 31, 2026 | News

Medidata Launches AI Layer to Scale Clinical Intelligence Across Global Trial Portfolios

Built on an award-winning AI foundation, Medidata Plus removes traditional barriers, empowering sponsors and CROs to scale intelligence across entire portf...

July 31, 2026 | News

Seegene Advances Comprehensive HPV and STI PCR Testing with Large-Scale Clinical Evidence

STAgora™ analysis of approximately 60,000 test results collected over 42 months showed that STI pathogens were detected in 82% of HPV-positive case...

July 29, 2026 | News

Stopped: The Six-Year Cost of Trials That Never Reached the Finish Line

One infusion, no programme A gene therapy is a one-way door. The vector goes in once, it cannot be taken out, and with current adeno-associated virus tech...

July 28, 2026 | Analysis

OrbusNeich Enrols First Patient in Pivotal Japanese Trial of Coronary Drug-Coated Balloon

OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a multinational medical device comp...

July 28, 2026 | News

AnHorn Medicines Advances First-in-Class AH-008 into Phase I Trial for Chemotherapy-Induced Neuropathy Prevention

AnHorn Medicines announced the successful completion of the first subject first dose in the Phase I clinical trial of AH-008, a first-in-class neuroprotect...

July 27, 2026 | News

Harbour BioMed Forecasts Record H1 2026 Profit as Strategic Partnerships Drive Growth

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutic...

July 27, 2026 | Company results

ArkBio Completes Dosing in Phase I Trial of Long-Acting Influenza Prevention Candidate AK0406

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial w...

July 27, 2026 | News

Laminar Pharma Completes Pivotal Phase 2b/3 Trial of LAM561 in Newly Diagnosed Glioblastoma

Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, announced that the last patient has c...

July 27, 2026 | News

Ribo’s Vortosiran Achieves 92% FXI Activity Reduction in Phase 2a Coronary Artery Disease Study

Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") today announce at C...

July 24, 2026 | News

Stay Connected